We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current ACAD market cap is 2.7B. The company's latest EPS is USD -0.3719 and P/E is -44.90.
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 130.71M | 136.49M | 118.46M | 165.24M | 211.7M |
| Operating Income | -30.87M | -46.06M | -53.58M | 3.04M | -57.78M |
| Net Income | -27.18M | -41.73M | -43.02M | 1.11M | -65.18M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 339.08M | 441.76M | 484.15M | 517.24M | 726.44M |
| Operating Income | -246.55M | -286.59M | -170.44M | -223.6M | -73.38M |
| Net Income | -235.26M | -281.58M | -167.87M | -215.98M | -61.29M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 602.49M | 587.81M | 655.31M | 642.77M | 632.54M |
| Total Liabilities | 176.81M | 187.4M | 281.05M | 246.98M | 270.37M |
| Total Equity | 425.69M | 400.41M | 374.26M | 395.79M | 362.17M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 783.18M | 782.62M | 700.12M | 587.81M | 748.96M |
| Total Liabilities | 84.05M | 155.61M | 159.23M | 187.4M | 317.2M |
| Total Equity | 699.14M | 627.01M | 540.89M | 400.41M | 431.76M |
| Quarter End | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -90.18M | -114.04M | -17.93M | -9.73M | -68.69M |
| Investing | 90.99M | 73.24M | 192.52M | -1.77M | 32.35M |
| Financing | 6.59M | 8.2M | 1.47M | 6.94M | 19.7M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -151.13M | -136.17M | -125.66M | -114.04M | 16.7M |
| Investing | -165.84M | 192.51M | -71.1M | 73.24M | 32M |
| Financing | 371.85M | 81M | 18.16M | 8.2M | 25.13M |
| Market Cap | 2.7B |
| Price to Earnings Ratio | -44.90 |
| Price to Sales Ratio | 3.79 |
| Price to Cash Ratio | 14.59 |
| Price to Book Ratio | 6.37 |
| Dividend Yield | - |
| Shares Outstanding | 164.77M |
| Average Volume (1 week) | 1.83M |
| Average Volume (1 Month) | 1.41M |
| 52 Week Change | -18.20% |
| 52 Week High | 33.99 |
| 52 Week Low | 16.16 |
| Spread (Intraday) | 0.59 (3.47%) |
| Company Name | Acadia Pharmaceuticals Inc |
| Address |
251 little falls drive wilmington, delaware 19808 |
| Website | https://www.acadia-pharm.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
